MDM2 Degrader Formulation for Sustained p53 Pathway Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MDM2 small molecule inhibitors (SMIs) induce a p53/MDM2 feedback loop, leading to upregulation of MDM2 protein levels and inhibition of the p53 pathway, limiting their effectiveness in cancer therapy.
Innovation Solution
Development of a MDM2 degrader, (3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-((1R,4R)-4-(4-(1-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)piperidine-1-carbonyl)cyclohexyl)-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamide (Compound A), which selectively degrades MDM2 protein, stabilizing p53 and inducing apoptosis in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If MDM2 small molecule inhibitors (SMIs) are used to stabilize p53, then p53 levels increase, but MDM2 protein levels upregulate through feedback loop, limiting biological activity
Solution Approach 1:
The patent extracts the problematic feedback loop mechanism by using a degrader compound that selectively removes MDM2 protein through ubiquitin-mediated degradation, rather than merely inhibiting its interaction with p53. This takes out the upregulating factor (MDM2) from the system, preventing the feedback loop that limits SMI effectiveness.
Solution Approach 2:
The invention changes the fundamental parameter of MDM2 protein levels from inhibited/stabilized (as with SMIs) to actively degraded. By shifting from inhibition-based mechanism to degradation-based mechanism, the patent transforms how p53 is regulated, achieving sustained activation without the compensatory upregulation seen with SMIs.
2Reliability
If MDM2 SMIs are used to inhibit MDM2/p53 interaction, then p53 pathway is initially activated, but MDM2 upregulation occurs, inhibiting the pathway
Solution Approach 1:
The degrader compound provides continuous p53 pathway activation by maintaining low MDM2 levels through sustained degradation. Unlike SMIs that require continuous presence to block interaction, the degrader ensures continuous pathway activation by removing the inhibitory MDM2 protein, preventing the pathway from being shut down by feedback-induced MDM2 upregulation.
Solution Approach 2:
The patent exploits and redirects the feedback mechanism: instead of allowing MDM2 upregulation feedback to inhibit the pathway (as with SMIs), the degrader creates a degradation feedback loop where reduced MDM2 levels prevent further MDM2 synthesis, sustaining pathway activation. The feedback now reinforces rather than opposes the therapeutic effect.
3Strength
If MDM2 SMIs are administered, then initial p53 stabilization occurs, but feedback loop limits effectiveness in cancer therapy
Solution Approach 1:
The patent converts the harmful feedback loop into a beneficial mechanism. The cell's natural response to p53 activation (which normally upregulates MDM2 to suppress p53) is hijacked by the degrader: when the cell attempts to upregulate MDM2 in response to p53 stabilization, the degrader instead promotes degradation of the upregulated MDM2, turning the cell's resistance mechanism into a tool for enhancing therapy effectiveness.
Data Source
AI summary
The present invention relates to MDM2 degraders, their liquid formulations, and methods of use thereof for treating cancer.